HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter
MWN-AI** Summary
HCW Biologics Inc. has successfully regained compliance with the continued listing rules of Nasdaq following a recent determination by the Nasdaq Hearings Panel. The announcement, made on March 2, 2026, comes after the Panel found that the biopharmaceutical company met the necessary requirements, allowing it to maintain its presence on The Nasdaq Capital Market. HCW Biologics, which specializes in developing novel immunotherapies aimed at extending healthspan by mitigating chronic inflammation, emphasized the importance of this compliance for its ongoing operations and future capital raising efforts.
Dr. Hing C. Wong, the company’s Founder and CEO, expressed gratitude for the Panel’s decision, highlighting that regaining compliance permits continued access to public markets crucial for advancing the company’s pioneering immunotherapeutic drugs, which target autoimmune diseases, cancer, and other health conditions exacerbated by chronic inflammation.
HCW Biologics is known for its innovative approach to treating senescence-associated diseases through unique drugs like HCW9302, an interleukin-2 fusion molecule currently in Phase 1 clinical trials for alopecia areata. The firm is also exploring two promising preclinical candidates, HCW11-018b and HCW11-040, which aim to improve treatment efficacy for various cancers.
The company’s strategic focus on business development and its existing licensing agreements further underpin its growth potential. However, as a clinical-stage biopharmaceutical entity, HCW Biologics acknowledges the inherent risks and uncertainties in its forward-looking statements, tracking closely with market dynamics and regulatory landscapes. Overall, the regained Nasdaq compliance marks a significant step forward for HCW Biologics as it endeavors to deliver transformative treatments in the biopharmaceutical landscape.
MWN-AI** Analysis
As HCW Biologics Inc. (NASDAQ: HCWB) successfully regains compliance with Nasdaq’s continued listing rules, investors may view this milestone as a promising signal for the company’s financial health and strategic direction. This compliance decision, following an evaluation by the Nasdaq Hearings Panel, underscores HCW's commitment to its operational and financial obligations and re-establishes its ability to access public capital markets.
HCW Biologics is focused on developing groundbreaking immunotherapies aimed at addressing chronic inflammation and age-related diseases. The potential of its lead product candidate, HCW9302, and other proprietary molecules could position HCW at the forefront of an expanding biopharmaceutical market, particularly as the global healthcare landscape shifts towards innovative treatments for autoimmune and senescence-associated diseases. With the company currently engaged in clinical trials—specifically the Phase 1 study of HCW9302 in alopecia areata—investors should keep an eye on trial outcomes, as positive results could significantly enhance investor sentiment and drive stock performance.
Moreover, HCW’s proactive approach in business development, including recent licensing agreements for its proprietary molecules, indicates a well-rounded strategy to monetize its intellectual property while mitigating risk. This diversification could safeguard its revenues, which is particularly relevant in the inherently volatile biotech sector.
However, while HCW Biologics shows promise, potential investors should remain cognizant of risks, including regulatory hurdles and reliance on clinical trial successes. Therefore, while it may be an opportune moment to consider an investment in HCW Biologics due to regained Nasdaq compliance and its innovative pipeline, thorough due diligence is paramount, especially given the uncertainties inherent in biomedical research and the evolving market landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MIRAMAR, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and disease, today reported that, on February 26, 2026, the Nasdaq Hearings Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq” or the “Exchange”) found that the Company regained compliance with all continued listing rules of The Nasdaq Capital Market.
Dr. Hing C. Wong, the Company’s Founder and CEO, stated “We appreciate the discretion of the Nasdaq Panel to provide us with the time we needed to regain compliance with the Equity Rule. Regaining compliance allows us to continue to access the public markets for capital we need to advance our first-in-class immunotherapeutic drugs that we believe will transform the way we treat autoimmune diseases, cancer and other senescence-associated diseases.”
About HCW Biologics:
HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company’s immunotherapeutics represent a new class of drug that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation — and in doing so, improve patients’ quality of life and possibly extend longevity. Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to the cause for senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as indications that impact quality-of-life that are not life-threatening. The Company lead product candidate for its autoimmune program is HCW9302, subcutaneously injectable, first-in-kind interleukin-2 (“IL-2”) fusion molecule with a tissue-factor scaffold that was constructed using the Company’s TOBI™ platform technology. HCW9302 is currently being evaluated in a Phase 1 clinical study in patients with alopecia areata, which initiated in November 2025 (NCT07049328). The Company has identified two preclinical lead product candidates for internal development constructed with its proprietary TRBC drug discovery and development platform, constructed with a protein-based scaffold. HCW11-018b (“Big BiTE”) is a tetra-valent T-cell engager designed to address shortfalls of bi-specific T-cell engagers (BiTE) related to manufacturability, safety profile, and ability to treat a wide spectrum of solid tumors. HCW11-040 is a pembrolizumab-based, tetra-valent immune checkpoint inhibitor. To improve efficacy, HCW11-040 is equipped with other moieties in addition to pembrolizumab which neutralizes the immunosuppressive cytokine, TGF-?, and activates effector immune cell responses. A key aspect of the Company’s clinical development and financing strategy is to focus on its business development programs. To date, the Company has entered two licensing agreements in which it has licensed exclusive, worldwide rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/
Forward-Looking Statements:
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words and include, the Company’s ability to improve or extend healthspan; to extend longevity; to develop new immunotherapeutic treatments for chronic inflammation and age-related diseases; to develop treatments with its drug discovery platforms; the Company’s ability to execute its compliance plan and regain compliance with Nasdaq continued listing requirements; and the Company’s ability to raise additional funds. Similarly, statements that describe the Company’s objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements are based only on the Company’s current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The Company’s actual results may differ materially from those indicated in the forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 28, 2025, the latest Quarterly Report on Form 10-Q filed with the SEC on November 14, 2025, and in other filings filed from time to time with the SEC.
Company Contact:
Rebecca Byam
Chief Financial Officer
HCW Biologics Inc.
RebeccaByam@hcwbiologics.com
FAQ**
How does HCW Biologics Inc. (HCWB) plan to utilize the capital access regained from Nasdaq compliance to advance its immunotherapeutic drug pipeline?
What milestones does HCW Biologics Inc. (HCWB) envision achieving in the next year regarding the Phase 1 clinical study for HCW9302?
Can you elaborate on how HCW Biologics Inc. (HCWB) aims to differentiate its drug candidates like HCW11-018b and HCW11-040 from existing treatments in the market?
What specific risks does HCW Biologics Inc. (HCWB) identify in its forward-looking statements that could impact its drug development timeline and financial strategy?
**MWN-AI FAQ is based on asking OpenAI questions about HCW Biologics Inc. (NASDAQ: HCWB).
NASDAQ: HCWB
HCWB Trading
-4.93% G/L:
$0.5847 Last:
38,718 Volume:
$0.6014 Open:
